Metal transport and homeostasis within the human body: Toxicity associated with transport abnormalities

Current Medicinal Chemistry

Volumn 19, Issue 17, 2012, Pages 2738-2759

  Potocki, S ^a   Rowinska Zyrek, M ^a   Witkowska, D ^a   Pyrkosz, M ^a   Szebesczyk, A ^a   Krzywoszynska, K ^a   Kozlowski, H ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

Metal homeostasis; Toxicity; Transport

Indexed keywords

ALBUMIN; ALUMINUM; ARSENIC; CADMIUM; CHROMIUM; CHROMIUM DERIVATIVE; COPPER; COTRANSPORTER; IRON; MANGANESE; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; METHYLCYCLOPENTADIENYLMANGANESE TRICARBONYL; NEUROMELANIN; NICKEL; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; ZINC; ZINC TRANSPORTER;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD BRAIN BARRIER; BRONCHITIS; CANCER RISK; CELL DEGENERATION; CELL DIVISION; CELL POPULATION; CHELATION THERAPY; CHRONIC LIVER FAILURE; DERMATITIS; DIALYSIS; DIALYSIS ENCEPHALOPATHY; DNA DAMAGE; DNA REPAIR; DOWN SYNDROME; DRUG MEGADOSE; DYSTONIA; ECZEMA; EUKARYOTIC CELL; FOLLOW UP; GLIA CELL; HOMEOSTASIS; HUMAN; HYPOKINESIA; INDIAN CHILDHOOD CIRRHOSIS; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON TRANSPORT; ISCHEMIA; LEUKOPENIA; LUNG CANCER; LYMPHADENOPATHY; MEMBRANE TRANSPORT; MENKES SYNDROME; METAL BINDING; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOSE CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PROKARYOTIC CELL; RESTLESS LEGS SYNDROME; RIGIDITY; SIDEROBLASTIC ANEMIA; SUBSTANTIA NIGRA PARS COMPACTA; TOTAL PARENTERAL NUTRITION; TREMOR; VASCULAR DISEASE; WILSON DISEASE; X CHROMOSOME LINKED DISORDER;

EID: 84861942728     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800609698     Document Type: Article

References (287)

1. Nordberg, M.; Kojima, Y. Metallothionein, Basel/Boston/Stuttgart, 1979, pp. 41-116.
2. Nordberg, M. Ethnic Differences in Reactions to Drugs and Xenobiotics, New York, 1986, pp. 401-410.
3. Lu, J.; Jin, T.; Nordberg, G.; Nordberg, M. Metallothionein gene expression in peripheral lymphocytes from cadmium-exposed workers Cell Stress Chap. 2001, 6, 97-104.
4. Sato, M.; Kondoh, M. Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. J. Exp. Med., 2002, 196, 9-22.
5. Lazo, J.S.; Kondo, Y.; Dellapiazza, D.; Michalska, A.E.; Choo, K.H.A.; Pit, B.R.; Enhenced selectivity of oxidative stress in cultured embryonic cells from transgenic cells from transgenic mice deficient in metallothionein I and II gene. J. Biol. Chem., 1995, 270, 5506-5510.
6. Nordberg, M.; Nordberg, G.F. Metallothioneins: Historical Development and Overview. Met. Ions Life Sci. 2009, 5, 1-29.
7. Vašák, M.; Berger, C.; Kägi J.H.R. Dynamic structure of metallothionein. Federation of European Blochemxal Socletles, 1984, 168, 174-178.
8. Elinder, C.-G.; Nordberg, M.; Cadmium and Health, Vol. I, CRC Press, Boca Raton, Fla,1985, pp. 65-79.
9. Nordberg, G.F.; Kjellström, T.; Nordberg, M. Cadmium and Health, Vol. I, CRC Press, Boca Raton, Fla, 1985, pp. 103-197.
10. Liu, X; Jin, T.; Nordberg, G.F.; Sjöström, M.; Zhou, Y. Influence of zinc and copper administration on metal disposition in rats with cadmiummetallothionein- induced nephrotoxicity. Toxicol. Appl. Pharmacol., 1994, 126, 84-90.
11. Aschner, M.; West, A.K.The role of MT in neurological disorders, J. Alzheimers Dis., 2005, 8, 139-145.
12. Maret, W. Metals on the move: zinc ions in cellular regulation and in the coordination dynamics of zinc proteins., Biomet., 2011, 24, 411-418.
13. Parkin, G. Synthetic analogues relevant to the structure and function of zinc enzymes. Chem. Rev., 2004, 104, 699-767.
14. Auld, D.S. Encyclopedia of Inorganic Chemistry; Wiley, Chichester, U.K., 2005, p. 5884.
15. 2+ Ions Transporter. Inorg. Chem., 2011, 50, 6135-6145.
16. Krzywoszynska, K.; Rowinska-Zyrek, M.; Witkowska, D.; Potocki, S.; Luczkowski, M.; Kozlowski, H. Polythiol binding to biologically relevant metal ions, Dalton Trans., 2011, doi:10.1039/C1DT10562K.
17. Vallee, B.L.; Auld, D.S. Biochemistry, Zinc coordination, function and structure of zinc enzymes and other proteins. 1990, 29, 5647-5659.
18. Frederickson, C.J.; Koh, J.Y.; Bush Al. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 2005, 6, 449-62.
19. Kim, B.J.; Kim, Y.H.; Kim, S.; Kim, J.W.; Koh, J.Y.; Oh, S.H.; Lee, M.K.; Kim, K.W.; Lee, M.S. Zinc as a paracrine effector in pancreatic islet cell death. Diabetes, 2000, 49, 367-72.
20. Choi, D.W.; Koh, J.Y. Zinc and brain injury. Annu. Rev. Neurosci., 1998, 21, 347-75.
21. Liu, G.; Huang, W.; Moir, R.D.; Vanderburg, C.R.; Lai, B.; Peng, Z.; Tanzi, R.E.; Rogers, J.T.; Huang, X. Metal exposure and Alzheimer's pathogenesis. J. Struct. Biol., 2006, 155, 45-51.
22. Maret, W.; Sandstead, H.H. Zinc requirements and the risks and benefits of zinc supplementation. J Trace Elem. Med. Biol., 2006, 20, 3-18.
23. Maret, W. Cellular zinc and redox states converge in the metallothionein/thionein pair., J. Nutr., 2003, 133, 1460-1462.
24. Krezel, A.; Maret, W. Dual nanomolar and picomolar Zn(II) binding properties of metallothionein., J. Am. Chem. Soc., 2007, 129, 10911-21.
25. Stewart, A.J.; Blindauer, C.A.; Berezenko, S.;Sleep, D.; Sadler, P.J. Interdomain zinc site on human albumin., Proc. Natl. Acad. Sci., 2003, 100, 3701-3706.
26. Churchich, J. E.; Scholz, G.; Kwok, F. Activation of pyridoxal kinase by metallothionein. Biochim. Biophys. Acta 1989, 996, 181-6.
27. Liuzzi, J.P.; Cousins, R.J. Mammalian zinc transporters. Annu. Rev. Nutr., 2004, 24, 151-72.
28. Eide, D.J. The SLC39 family of metal ion transporters., Pflugers Arch., 2004, 447, 796-800.
29. 2+ currents are mediated by calcium-permeable AMPA/Kainate channels in cultured murine hippocampal neurons, J. Physiol., 2002, 543, 35-48.
30. Vogt, K.; Mellor, J.; Tong, G.; Nicoll, R. The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron, 2000, 26, 187-196.
31. Schmitt-Ulms, G.; Ehsani, S.; Watts, J.C; Westaway, D.; Wille, H. Evolutionary descent of prion genes from the ZIP family of metal ion transporters., PLoS ONE, 2009, 4, e7208.
32. Guffanti, A.A.; Wei, Y.; Rood, S.V.; Krulwich, T.A. An antiport mechanism for a member of the cation diffusion facilitator family: divalent cations efflux in exchange for K+ and H, Molecul. Microbiol., 2002, 45, 145-153.
33. Chao, Y.; Fu, D. Kinetic study of the antiport mechanism of an Escherichia coli zinc transporter, ZitB., J. BIOL. CHEM., 2004, 279, 12043-12050.
34. Lee, S.M.; Grass, G.; a, Haney, C.J.; Fan, B.; Rosen, B.P.; Anton, A.; Nies, D.H.; Rensing, C. Functional analysis of the Escherichia coli zinc transporter ZitB., FEMS Microbil. Lett., 2002, 215, 273-278.
35. Rogers, E.E.; Eid, D.J. Altered selectivity in an Arabidopsis metal transporter, PNAS, 2000, 97, 12356-12360.
36. Huang, L.; Kirschke, C.P.; Zhang, Y.; Yu, Y.Y. The ZIP7 Gene (Slc39a7) Encodes a Zinc Transporter Involved in Zinc Homeostasis of the Golgi Apparatus, J. Biol. Chem. 2005, 280, 15456-15463.
37. Nies, D.H. How cells control zinc homeostasis. Science 2007, 317, 1695-1696.
38. Lu, M.; Chai, J.; Fu, D. Structural Basis for Auto-regulation of the Zinc Transporter YiiP. Nat Struct Mol Biol, 2009, 16, 1063-1067.
39. Lin, W.; Chai, J.; Love, J.; Fu, D. Selective Electrodiffusion of Zinc Ions in a Zrt-, Irt-like ZIPB. J. Biol. Chem., 2010, 285, 39013-39020.
40. Franklin, R.B.; Ma, J.; Zou, J.; Guan, Z.; Kukoyi, B.I.; Feng, P.; Costello, L.C. Human ZIP1 is a major zinc uptake transporter for the accumulation of zinc in prostate cells. J. Inorg. Biochem., 2003, 96 435-442.
41. 2+/H+ Antiporter of Arabidopsis thaliana, Stimulates the Transport Activity. J. Biol. Chem., 2008, 283, 8374-8383.
42. 2+-stimulated endocytosis of the mZIP4 zinc transporter regulates its location at the plasma membrane., 2004, 279, 4523-4530.
43. Kuery, S.; Dreno, B.; Bezieau, S.; Giraudet, S.; Kharfi, M.; Kamoun, R.; Moisan, J.-P. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica., 2002, 239-240.
44. Wang, K.; Zhou, B.; Kuo, Y.-M.; Zemansky, J.; Gitschier, J. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica., Am. J. Hum. Genet., 2002, 71, 66-73.
45. Ota, T.; Suzuki, Y.; Nishikawa, T.; Otsuki, T.; Sugiyama, T.; Irie, R.; Wakamatsu, A.; Hayashi, K.; Sato, H.; Nagai, K.; Kimura, K.; Makita, H.; Sekine, M.; Obayashi, M.; Nishi, T.; Shibahara, T.; Tanaka, T.; Ishii, S.; Sugano, S. Complete sequencing and characterization of 21,243 full-length human cDNAs., Nat. Genet., 2004, 36, 40-45.
46. Taylor, K.M.; Morgan, H.E.; Johnson, A.; Hadley, L.J.; Nicholson, R.I. Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters., Biochem. J., 2003, 375, 51-59.
47. Manning, D.L.; Daly, R.J.; Lord, P.G.; Kelly, K.F.; Green, C.D. Effects of oestrogen on the expression of a 4.4 kb mRNA in the ZR-75-1 human breast cancer cell line., Mol. Cell. Endocrinol., 1988, 59, 205-212.
48. Bly, M.; "Examination of the zinc transporter gene, SLC39A12. PubMed, 2006, 81, 321-322.
49. Wistow, G.; Bernstein, S.L.; Wyatt, M.K.; Fariss, R.N.; Behal, A.; Touchman, J.W.; Bouffard, G.; Smith, D.; Peterson K. Expressed sequence tag analysis of human RPE/choroid for the NEIBank project: over 6000 nonredundant transcripts, novel genes and splice variants., Mol. Vis., 2002, 8, 205-220.
50. Suzuki, Y.; Yamashita, R.; Shirota, M.; Sakakibara, Y.; Chiba, J.; Mizushima-Sugano, J.; Nakai, K.; Sugano, S. Sequence comparison of human and mouse genes reveals a homologous block structure in the promoter regions. Genome Res., 2004, 14, 1711-1718.
51. Giunta, C.; Elcioglu, N.H.; Albrecht, B.; Eich, G.; Chambaz, C.; Janecke, A.R.; Yeowell, H.; Weis, M.; Eyre, D.R.; Kraenzlin, M. Steinmann B.Spondylocheiro dysplastic form of the Ehlers-Danlos syndrome - an autosomal-recessive entity caused by mutations in the zinc transporter gene SLC39A13., 2008, Am. J. Hum. Genet., 2008, 82, 1290-1305.
52. Chimienti, F.; Devergnas, S.; Pattou, F.; Schuit, F.; Garcia-Cuenca, R.; Vandewalle, B.; Kerr-Conte, J.; Van Lommel, L.; Grunwald, D.; Favier, A.; Seve, M. In vivo expression and functional characterization of the zinc transporter ZnT8 in glucose-induced insulin secretion., J. Cell Sci., 2006, 119, 4199-4206.
53. Seve, M.; Chimienti, F.; Devergnas, S.; Favier, A. In silico identification and expression of SLC30 family genes: an expressed sequence tag data mining strategy for the characterization of zinc transporters' tissue expression., BMC Genomic, 2004, 5, 32.
54. Smith, J.L.; Xiong, S.; Markesbery, W.R.; Lovell, M.A. Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain., 2006, 140, 879-888.
55. Sim, D.L.C.; Chow, V.T.K. The novel human HUEL (C4orf1) gene maps to chromosome 4p12-p13 and encodes a nuclear protein containing the nuclear receptor interaction motif., Genomics, 1999, 59, 224-233.
56. Ettinger, M.J. In: Copper Proteins and Copper Enzymes; Lontie, R. Ed.; CRC Press, Boca Raton: FL.,1984; 175-229.
57. Roberts, E.A.; Schilsky, M.L. Diagnosis and treatment of Wilson disease: An update. Hepatology, 2008, 47, 2089-2111.
58. Linder, M.C.; Lomeli, N.A.; Donley, S.; Mehrbod, F.; Cerveza, P.; Cotton. S.; et al. In: Copper transport and its disorders; Leone, A.; Mercer, J.F.B., Ed.; Kluwer Academic/Plenum : New York, 1999; pp. 1-16.
59. Stevens, M.D.; DiSilvestro, R.A.; Harris, E.D. Specific receptor for ceruloplasmin in membrane fragments from aortic and heart tissues. Biochemistry, 1984, 23, 261-6.
60. Holmberg, C.G.; Laurell, C.B. Investigations in serum copper. Acta Chem. Scand., 1948, 2, 550-556.
61. Linder, M.C.; Hazegh-Azam, M. Copper biochemistry and molecular biology. Am. J. Clin. Nutr., 1996, 63,797S-811S.
62. Rozga, M.; Sokołowska, M.; Protas, A.M.; Bal, W. Human serum albumin coordinates Cu(II) at its N-terminal binding site with one picomolar affinity. J. Biol. Inorg. Chem ., 2007, 12, 913-918.
63. 2+ interactions with N-terminal fragments of Hpn and Hpn-like proteins from Helicobacter pylori : unusual impact of poly-Gln sequence on the complex stability. J. Inorg. Biochem., 2011, 105 , 208-214.
64. Jitsukawa, K.; Harata, M.; Ariia, H.; Sakurai H.; Masuda, H. SOD activities of the copper complexes with tripodal polypyridylamine ligands having a hydrogen bonding site. Inorg. Chim. Acta, 2001, 324(1-2), 108-116.
65. Weder, J.E.;,Dillon, C.T.; Hambley, T.W.;, Kennedy, B.J.;, Lay, P.A.;, Biffin, J.R.;, Regtop, H.L.;, Davies N.M. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. Coord. Chem. Rev., 2002, 232 (1-2), 95-126.
66. Stańczak, P.; Kozłowski, H. Can chicken and human PrPs possess SOD-like activity after ß-cleavage? Biochem. Biophys. Res. Commun., 2007, 352 , 198-202.
67. Daniel, K.G.; Harbach, R.H.; Guida, W.C.; Dou, Q.P. Copper storage diseases: Menkes, Wilsons, and cancer. Front. Biosci., 2004, 9, 2652-62.
68. Marzano, C.; Pellei, M.; Tisato, F.; Santini, C. Copper complexes as anticancer agents. Anticancer Agents Med. Chem., 2009, 9(2), 185-211.
69. Tardito, S.; Marchio, L. Copper Compounds in Anticancer Strategies. Current Med. Chem., 2009, 16(11),1325-1348.
70. Wang , I.; Hodgkinson, V.; Zhu, S.; Weisman, G.A.; Petris, M.J. Advances in the Understanding of Mammalian Copper Transporters. Adv. Nutr., 2011, 2, 129-137.
71. Culotta, V.C.; Klomp, L.W.; Strain, J.; Casareno, R.L.; Krems, B.; Gitlin, J.D. The copper chaperone for superoxide dismutase. J. Biol. Chem., 1997, 272, 23469-23472.
72. Srinivasan, C.; Posewitz, M.C.; George O.N.; Winge, D.R. Characterization of the copper chaperone Cox17 of Saccharomyces cerevisiae. Biochemistry, 1998, 37, 7572-7577.
73. Pufahl, R.A.; Singer, C.P.; Peariso, K.L.; Lin, S.J.; Schmidt, P.J.; Fahrni, C.J.; et al. Metal Ion Chaperone Function of the Soluble Cu(I) Receptor Atx1. Science, 1997, 278, 853-856.
74. Palm, M.E.; Weise, Ch.F.; Lundin, Ch.; Wingsle, G.; Nygren, Y.; Björn, E.; Naredi, P.; Wolf-Watz, M.; Wittung-Stafshede, P. Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro. PNAS, 2011, 108, 6951-6956.
75. Kaplan J.H.; Lutsenko, S. Copper transport in mammalian cells: special care for a metal with special needs. J. Biol. Chem., 2009, 284(38), 25461-25465.
76. Abajian, C.; Yatsunyk, L. A.; Ramirez, B. E.; Rosenzweig, A. C. Yeast cox17 solution structure and Copper(I) binding. J.Biol. Chem., 2004, 279, 53584-92.
77. Freedman, J.H.; Ciriolo, M.R.; Peisach, J. The role of glutathione in copper metabolism and toxicity. J. Biol. Chem., 1989, 264, 5598-605.
78. Cousins, R. Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. J. Physiol. Rev., 1985, 65, 238-309.
79. Abrahams, I.L.; Bremner, I.; Diakun, G.P.; Garner, C.D.; Hasnain, S.S.; Ross, I.; Vasák, M. Structural study of the copper and zinc sites in metallothioneins by using extended X-ray-absorption fine structure. Biochem. J., 1986, 236, 585-589.
80. Stillman, M.J. Metallothioneins. Coord. Chem. Rev., 1995, 144, 461-511.
81. Kozłowski, H.; Brown, D.; Valensin, G. In Metallochemistry of Neurodegeneration: Biological, Chemical and Genetic Aspects.; RSC Publishing, Cambridge, 2006; pp.1-281.
82. Menkes, J.H.; Alter, M.; Steigleder, G.K.; Weakley, D.R.; Sung, J.H. A sexlinked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics, 1962, 29, 764-79.
83. Wilson, SAK. Progressive lenticular degenera- tion: A familial nervous disease associated with cirrhosis of the liver. Brain, 1912, 34, 295-509.
84. Muller, T.; Muller, W.; Feichtinger, H. Idiopathic copper toxicosis. Am. J. Clin. Nutr., 1998, 67(Suppl), 1082-6S.
85. Schneiberg, I.H.; Sternlieb, I. Wilson disease and idiopathic copper toxicosis. Am. J. Clin. Nutr. 1996, 63, 842-5S.
86. Danks, D.M. In: The Metabolic and Molecular Bases of Inherited Disease; Scriver, C.R.; Beaudet, A.L.; Sly, W.S.; Valle, D. Ed.; McGraw-Hill: NewYork, 1989; pp. 1411-31.
87. Kaler, S.G.; Buist, N.R.; Holmes, C.S.; Goldstein, D.S.; Miller, R.C.; Gahl, W.A. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann. Neurol., 1995, 38(6), 921-8.
88. Munakata, M.; Sakamoto, O.;, Kitamura, T.;, Ishitobi, M.;, Yokoyama, H.;, Haginoya, K.;, Togashi, N.; et all. The effects of copper-histidine therapy on brain metabolism in a patient with Menkes disease: a proton magnetic resonance spectroscopic study. Brain and Development, 2005, 27 (4), pp. 297-300.
89. Tapiero, H.; Townsend, D.M.; Tew, K.D. Trace elements in human physiology and pathology.Copper. Biomed. Pharmacother. 2003, 57(9), 386-98.
90. Tanner, M. S. Role of copper in Indian childhood cirrhosis. The American Journal of Clinical Nutrition, 1998, 67(5 Suppl), 1074S-1081S.
91. Ala, A.; Walker, A.P.; Ashkan, K.; Dooley, J.S.; Schilsky, M.L. Wilson's Disease. Lancet. 2007, 369, 397-408.
92. Crisponi, G.; Nurchi, V.M.; Fanni, D.; Gerosa, C.; Nemolato, S.; Faa, G. Copper-related diseases: From chemistry to molecular pathology, Coord. Chem. Rev., 2010, 254 , 876-889.
93. Pfeiffer, R.F. Wilson's Disease. Semin. Neurol., 2007, 27(2), 123-132.
94. Brewer, G.J. Wilson's Disease: A Clinician's Guide to recognition, Diagnosis, and Management; Kluwer Academic Publishers: Boston, 2001.
95. Schmitt de Bem R. et al. Wilson's disease in southern Brazil: a 40-year follow-up study. Clinical science, 2011, 66(3), 411-416.
96. Brown, D.R. Metals in neurodegenerative disease. Metallomics, 2011, 3, 226-228.
97. Valentine, J.S.: Hart P.J.; Gralla, E.B. In: Copper transport and its disorders; Leone, A.; Mercer, J.F.B, Ed.; Kluwer Academic/Plenum: NewYork, 1999, pp. 193-203.
98. Johnson, M.A.; Macdonald, T.L.; Mannick, J.B.; Conaway, M.R.; Gaston ,B. Accelerated s-nitrosothiol breakdown by amyotrophic lateral sclerosis mutant copper,zinc-superoxide dismutase. J. Biol. Chem., 2001, 276, 39872-39878.
99. Chattopadhyay, M.; Valentine, J.S. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid. Redox Signal., 2009 , 11(7), 1603-1614.
100. Altschuler, E. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med. Hypotheses, 1999, 53, 22.
101. Hardy, J.; Selkoe, D. J. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics. Science, 2002, 297, 353-356.
102. De Ferrari, G. V.; Inestrosa, N. C. Wnt signaling function in Alzheimer's disease. Brain Res. Rev. 2000, 33, 1.
103. Schoneich, C. Redox Processes of Methionine Relevant to β-Amyloid Oxidation and Alzheimer's Disease. Arch. Biochem. Biophys. 2002, 397, 370.
104. Multhaup, G.; Ruppert, T.; Schlicksupp, A.; Hesse, L.; Eckhard, E.; Pipkorn, R.; Masters, C. L.; Beyreuther, K. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry, 1998, 37, 7224.
105. Gaggelli, E.; Kozłowski, H.; Valensin, D.; Valensin, G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem.Rev., 2006, 106, 1995-2044.
106. Kozlowski, H.; Janicka-Klos, A.; Brasun, J.; Gaggelli, E.; Valensin, D.; Valensin, G.; Copper, iron, and zinc ions homeostasis and their role in neurodegenerative disorders (metal uptake, transport, distribution and regulation), Coord. Chem. Rev., 2009, 253,2665-2685.
107. Bleackley, M.R.; MacGillivray, R.T.A.; Transition metal homeostasis: from yeast to human disease. Biometals, published online: 10 April 2011.
108. German, D. C., Manaye, K. F., White, C. L. III, Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N. & Mann, D. M. Disease-specific patterns of locus coeruleus cell loss. Annals of Neurology, 32, 667-676.
109. Zecca, L.; Stroppolo, A.; Gatti, A.; Tampellini, D.; Toscani, M.; Gallorini, M.; Giaveri, G.; Arosio, P.; Santambrogio, P.; Fariello, R.G.; Karatekin, E.; Kleinman, M.H.; Turro, N.; Hornykiewicz, O.; Zucca, F.A.; The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proceedings of National Academy of Science U.S.A. 2004, 101,9843-9848.
110. Zucca, F. A.; Belle, C.; Giannelli, S.; Terreni, M. R.; Gallorini, M.; Rizzio, E.; Pezzoli, G.; Albertini, A.; Zecca L.; Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. Journal Neural Transmission, 2006, 113, 757-767.
111. Gorell, J.M.; Ordidge, R.J.; Brown, G.G.; Deniau, J.C.; Buderer, N.M.; Helpern, J.A.; Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology, 1995, 45, 1138-1143.
112. Francois, C.; Nguyen-Legros, J.; Percheron, G.; Topographical and cytological localization of iron in rat and monkey brains. Brain Research, 1981, 215, 317-322.
113. Sofic, E.; Riederer, P.; Heinsen, H.; Beckmann, H.; Reynolds, G.P.; Hebenstreit, G.; Youdim, M.B.; Increased iron (II1) and total iron content post mortem substantia nigra of parkinsonian brain. Journal of Neural Transmission, 1988, 74, 199.
114. Hirsch, E.C.; Iron transport in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15S3, S209-S211.
115. Robb, S.J.; Robb-Gaspers, L.D.; Scaduto, R.C. Jr.; Thomas, A.P.; Connor, J.R.; Influence of calcium and iron on cell death and mitochondrial function in oxidatively stressed astrocytes, Journal of Neuroscience Research, 1999, 55, 674-686.
116. Snyder, A.M.; Connor, J.R.; Iron, the substantia nigra and related neurological disorders. Biochimica et Biophysica Acta, 2009,1790, 606-614.
117. Castellani R.J., Smith M.A., Nunomura A., Harris P.L., Perry G.; Is increased redox-active iron in Alzheimer disease a failure of the copperbinding protein ceruloplasmin? Free Radical Biology and Medicine 26, 1999, 1508-1512.
118. Connor J.R., Menzies S.L., St Martin S.M., Mufson E.J.; A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. Journal of Neurosciences Research, 1992, 31, 75-83.
119. Mantyh P.W., Ghilardi J.R., Rogers S., DeMaster E., Allen C.J., Stimson E.R., Maggio J.E.; Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. Journal of Neurochemistry, 1993, 61, 1171-1174.
120. Rogers J.T., Leiter L.M., McPhee J., Cahill C.M., Zhan S.S., Potter H., Nilsson L.N.; Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. Journal of Biological Chemistry 274:6421-6431 (1999)
121. Earley, C.J.; Heckler, D.; Allen, R.P.; The treatment of restless legs syndrome with intravenous iron dextran, Sleep Medicine, 2004, 5, 231-235.
122. Connor, J.R.; Wang, X.S.; Patton, S.M.; Menzies, S.L.; Troncoso, J.C.; Earley, C.J.; Allen, R.P.; Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology, 2004, 62, 1563-1567.
123. Barton, J.C.; Wooten, V.D.; Acton, R.T.; Hemochromatosis and iron therapy of restless legs syndrome. Sleep Medicine, 2001, 2, 249-251.
124. Burdo, J.R.; Connor J.R.; Brain iron uptake and homeostatic mechanisms: An overview. BioMetals, 2003, 16, 63-75.
125. Zheng, W.; Xin, N.; Chi, Z. H.; Zhao, B. L.; Zhang, J.; Li, J. Y.; Wang, Z. Y. Divalent metal transporter 1 is involved in amyloid precursor protein processing and Aß generation. Federation of American Society for Experimental Biology Journal, 2009, 23, 4207-4217.
126. Shayeghi, M.; Latunde-Dada, G.O.; Oakhill, J.S.; Laftah, A.H.; Takeuchi, K.; Halliday, N.; Khan, Y.; Warley, A.; McCann, F.E.; Hider, R.C.; Frazer, D.M.; Anderson, G.J.; Vulpe, C.D.; Simpson, R.J.; McKie, A.T.; Identification of an intestinal heme transporter. Cell, 2005, 122, 789.
127. Crichton R.R., Wilmet S., Legssyer R., Ward R.;J Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. Journal of Inorganic Biochemistry, 2002, 91, 9-18.
128. Goswami T., Rolfs A., Hediger M.A.; Iron transport: emerging roles in health and disease. Biochemistry of Cell Biology, 2002, 80, 679-689.
129. Gaasch, J.A.; Lockman, P.R.; Geldenhuys, W.J.; Allen, D.D.; Van der Schyf, C.J.; Brain Iron Toxicity: Differential Responses of Astrocytes, eurons, and Endothelial Cells. Neurochemistry Research, 2007, 32, 1196.
130. Bishop G.M., Robinson S.R., Quantitative analysis of cell death and ferritin expression in response to cortical iron: implications for hypoxia-ischemia and stroke. Brain Research, 2001, 907, 175-187.
131. Ying W., Han S.K., Miller J.W., Swanson R.A.; Acidosis potentiates oxidative neuronal death by multiple mechanisms. Journal of Neurochemistry, 1999, 73, 1549-1556.
132. Breuer W., Greenberg E., Cabantchik Z.I.; Newly delivered transferrin iron and oxidative cell injury. FEBS Lett, 1997, 403, 213-219.
133. Calabrese V., Lodi R., Tonon C., D'Agata V., Sapienza M., Scapagnini G., Mangiameli A., Pennisi G., Stella A.M., Butterfield D.A.; Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. Journal of Neuroligal Sciences, 2005, 233, 145-162.
134. Robb S.J., Robb-Gaspers L.D., Scaduto R.C. Jr, Thomas A.P., Connor J.R.; Influence of calcium and iron on cell death and mitochondrial function in oxidatively stressed astrocytes. Journal of Neuroscience Research, 1999, 55, 674-686.
135. Wright, O.R.; Baccarelli, A. Metals and Neurotoxicology. J.Nutr., 2007, 137, 2809-2813.
136. Kozłowski, H.; Brown, R.D.; Valensin, G. Metallochemistry of Neurodegeneration. Biological, Chemical and Genetic Aspects, RSC Publishing, UK, 2006; pp. 97-113.
137. Archibald, F.S.; Tyree, C. Manganese poisoning and the attack of trivalent manganese upon catecholamines. Arch. Biochem. Biophys., 1987, 256, 638-650
138. Jursa, T.; Smith, D.R. Ceruloplasmin alters the tissue disposition and neurotoxicity of manganese, but not its loading onto transferrin. Toxicological Sciences, 2009, 107, 182-193.
139. Keen, C.L., 1995. Overview of manganese toxicity. In: Velazquez, S., EPA Liaison (Eds.), Proceedings of the Workshop on the Bioavailability and Oral Toxicity of Manganese. US EPA, Environmental Criteria and Assessment Office, pp. 3-11.
140. Erikson, K.M. ; Syversen, T.; Aschner, J.; Aschner, M. Interactions between excessive manga- nese-exposure and dietary iron-deficiency in neurodegeneration. Environ Toxicol Pharmacol., 2005, 19, 415-21.
141. Keen, C.L.; Ensunsa, J.L.; Clegg, M.S. Manganese metabolism in animals and humans including the toxicity of manganese. In Manganese and its Role in Biological Processes, Sigel, A.; Sigel, H. (eds). Marcel Dekker: New York, 2000, 89-121.
142. Carl, G.F.; Gallagher, B.B. Manganese and epilepsy. In Manganese in Health and Disease, Klimis-Tavantzis DJ (ed.). CRC Press:Boca Raton, FL, 1994, 133-143.
143. Shishova, E.Y.; Di Costanzo, L.; Emig, F.A.; Ash, D.E.; Christianson, D.W. Probing the specificity determinants of amino acid recognition by arginase. Biochemistry, 2009, 48, 121-131.
144. Takeda, A. Manganese action in brain function. Brain Research Reviews, 2003, 41, 79-87.
145. Keen, C.L., Ensunsa, J.L.; Clegg, M. S. Manganese metabolism in animals and humans including the toxicity of manganese. Metal Ions in Biological Systems, 2000, 37, 89-121.
146. Hardy, G. Manganese in parenteral nutrition: who, when,and why should we supplement? Gastroenterology, 2009, 137, S29-S35.
147. Krieger, D.; Krieger, S.; Jansen, O.; Gass, P.; Theilmann, L.; Lichtnecker, H. Manganese and chronic hepatic encephalopathy. Lancet, 1995, 346, 270-274.
148. Wasserman, G. A.; Liu, X.; Parvez, F. Water manganese exposure and children's intellectual function in Araihazar, Bangladesh. Environmental Health Perspectives, 2006, 114,124-129.
149. Krachler, M.; Rossipal, E. Concentrations of trace elements in extensively hydrolysed infant formulae and their estimated daily intakes. Annals of Nutrition and Metabolism, 2000, 44, 68-74.
150. Finkelstein, M. M.; Jerrett, M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environmental Research, 2007, 104, 420-432.
151. Walsh, M. P. The global experience with lead in gasoline and the lessons we should apply to the use of MMT. American Journal of Industrial Medicine, 2007, 50, 853-860.
152. Barbeau, A. Manganese and extrapyramidal disorders. Neurotoxicology, 1984, 5, 13-35.
153. Barbeau, A.; Inoué, N.; Cloutier, T. Role of manganese in dystonia. Adv.Neurol., 1976, 14, 339-352.
154. Mena, I.; Marin, O; Fuenzalida, S.; Cotzias, G.C. Chronic manganese poisoning. Clinical picture and manganese turnover. Neurology , 1967, 17, 128-136.
155. Herrero Hernández, E.; Discalzi, G.; Valentini, C.; Venturi, F.; Chio, A.; Carmellino, C. Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA. Neurotoxicology, 2006, 27, 333-339.
156. Michael, A.; Tomás, R.G.; Jay, S.S.; Zheng ,W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol. Appl. Pharmacol., 2007, 221, 131-147.
157. Michael, S.M.; James, L.B.; Nazzareno, B. Hepatic uptake and biliary excretion of manganese in the little skate, Leucoraja erinacea. Comp.Biochem.Physiol.C., 2009, 149, 566-571.
158. Fitsanakis, V.A.; Piccola, G.; Marreilha dos Santos, A.P.; Aschner, J.L. Putative proteins involved in manganese transport across the blood brain barrier. Hum Exp Toxicol., 2007, 26, 295-302.
159. Huang, P.; Chenn C.; Wang, H.; Li, G.; Jing, H.; Han, Y.; Liu, N.; Xiao, Y.; Yu, Q.; Liu, Y.; Wang, P.; Shi, Z.; Sun, Z. Manganese effects in the liver following subacute or subchronic manganese chloride exposure in rats. Ecotoxicology and Environmental Safety, 2011, 74, 615-622.
160. Roth , J.A. Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination. Biological Research, 2006, 39(1), 45-47.
161. Aschner, M.; Vrana, K.E.; Zheng, W. Manganese uptake and distribution in the central nervous system (CNS) Neurotoxicology, 1999, 20, 173-180.
162. Yokel, R.A. Manganese Flux Across the Blood-Brain Barrier. Neuromol Med., 2009, 11, 297-310.
163. Fitsanakis V.A.; Thompson, K.N.; Deery, S.E.; Milatovic, D. A chronic irondeficient/high-manganese diet in rodents results in increased brain oxidative stress and behavioral deficits in the Morris water maze. Neurotox Res., 2009, 15, 167-178.
164. Aschner, M.; Dorman, D. C. Manganese: Pharmacokinetics and molecular mechanisms of brain uptake. Toxicological Reviews, 2007, 25, 147-154.
165. Rabin, O.; Hegedus, L; Bourre, J.M.; Smith, Q.R. Rapid brain uptake of manganese (II) across the blood-brain barrier, J. Neurochem.,1993, 61, 509-517.
166. Wolburg, H.; Paulus, W. Choroid plexus: biology and pathology. Acta Neuropathol., 2010, 119, 75-88.
167. Laterra, J.; Keep, R.; Betz, L.A.; Goldstein, G.W. Blood- braincerebrospinal fluid barriers. In: Siegel, G.J.; Agranoff, B.W.; Albers ,R.W.; Fisher, S.K.; Uhler, M.D. Basic neurochemistry:molecular, cellular and medical aspects, 6th edn.Lippincott Williams & Wilkins, New York, pp 671-689.
168. Knopfel, M,; Zhao, L.; Garrick, M.D. Transport of divalent transition-metal ions is lost in small-intestinal tissue of b/b Belgrade rats. Biochemistry, 2005,44, 9, 3454-65.
169. Sacher, A.; Cohen, A.; Nelson, N.; Properties of the mammalian and yeast metal-ion transporters DCT1 and Smf1p expressed in Xenopus laevis oocytes. Journal of Experimental Biology, 2001, 204, 1053-1061.
170. Garcia, S. J.; Gellein, K.; Syversen, T.; Aschner, M. Iron deficient and manganese supplemented diets alter metals and transporters in the developing rat brain. Toxicological Sciences, 2007, 95, 205-214.
171. Gunshin, H.; Mackenzie, B.; Berger, U.V.; Gunshin ,Y. Cloning and characterization of a mammalian proteincoupled metal-ion transporter. Nature, 1997, 388, 482-488.
172. Siddappa, A.J; Rao R.B.; Wobken, J.D.; Leibold, E.A. Developmental changes in the expression of iron regulatory proteins and iron transport proteins in the perinatal rat brain. J Neurosci Res., 2002, 68, 761-775.
173. Crossgrove, J.S.; Yokel, R.A. Manganese distribution across the blood-brain barrier III; the divalent metal transporter-1 is not the major mechanism mediating brain manganese uptake. Neurotoxicology, 2004, 25, 451-460.
174. Crossgrove, J. S.; Allen, D. D.; Bukaveckas, B. L.; Rhineheimer, S. S.; Yokel, R. A. Manganese distribution across the blood-brain barrier. I. Evidence for carrier-mediated influx of manganese citrate as well as manganese and manganese transferring. Neurotoxicology, 2003, 24, 3-13.
175. Crossgrove, J.S.; Yokel, R.A. Manganese distribution across the blood-brain barrier. NeuroToxicology, 2005, 26, 297-307.
176. Nielsen, F.H. Is nickel nutritionally important? Nutrition Today, 1993, 28, 14-19.
177. Nielsen, F.H. In: Present Knowledge in Nutrition; Bowman, B.A. and Russel, R.M., Ed.; International Life Sciences Institute: Washington D.C, 2006, pp. 506-526.
178. Kaluarachchi, H.; Chan Chung, K.C.; Zambe D.B. Microbial nickel proteins. Nat. Prod. Rep., 2010, 27, 681-694.
179. Li, Y.; Zamble, D.B. Nickel homeostasis and nickel regulation: an overview, Chem. Rev., 2009, 109, 4617-4643.
180. Kowalik-Jankowska, T.; Kozłowski, H.; Farkas, E.; Sovago I. In: Nickel ion complexes of amino acids and peptides, Metal Ions in Life Sciences; Sigel, A. ; Sigel, H. ; .Sigel, R.K.O., Ed.; Wiley & Sons., 2007; Vol. 2, pp. 63-108.
181. Rowinska-Zyrek, M.; Witkowska, D.; Bielinska, S.; Kamysz, W.;Kozlowski, H. The -Cys-Cys- motif in Helicobacter pylori's Hpn and HspA proteins is an essential anchoring site for metal ions. Dalton Trans., 2011, 40, 5604-5610.
182. Rowinska-Zyrek, M.; Witkowska, D.; Valensin, D.; Kamysz, W.; Kozlowski, H. The C terminus of HspA-a potential target for native Ni(II) and Bi(III) anti-ulcer drugs. Dalton Trans., 2010, 39, 5814-5826.
183. Fontecilla-Camps, J.C. Biological nickel. Structure & Bonding, 1998, 91, 1-30.
184. Mulrooney, S. B.; Hausinger, R.P. Nickel uptake and utilization by microorganisms. FEMS Microbiol. Rev., 2003, 27 (2-3), 239-261.
185. Anke, M.; Angelow, L.; Glei, M.; Mu ller, M.; Illing, H. The biological importance of nickel in the food chain. Fresenius J. Ana.l Chem.,1995, 352, 92-96.
186. Barceloux, D.G. Nickel. Clin Toxicol., 1999, 37, 239-258.
187. Smith, R.L.; Maguire, M.E. Microbial magnesium transport: unusual transporters searching for identity. Mol. Microbiol., 1998, 28, 217-226.
188. Sutherland, J.E.; Costa, M. In: Heavy Metals in the Environment; B. Sarkar, Ed.; Marcel Dekker, New York, 2002, pp 349-407.
189. Christensen, J. M.; Kristiansen, J.; Nielsen, N. H.; Menne, T.; Byrialsen, K. Nickel concentrations in serum and urine of patients with nickel eczema. Toxicol. Lett., 1999, 108, 185-189.
190. Gropper, S.S.; Smith, J.L.; Groff, J.L.; Advanced nutrition and human metabolism, Wadsworth/Cengage Learning, Australia/United States, 2009.
191. Doll, R.; Morgan, L.G.; Speizer, F.E. Cancers of the lung and nasal sinuses in nickel workers. Br. J. Cancer, 1970, 24, 623-632.
192. Agency for Toxic Substances and Disease Registry: Toxicological Profile for Nickel, (http://www.atsdr.cdc.gov/toxprofiles/TP.asp?id=245&tid=44 (Accessed August 2005)
193. Ermolli, M.; Menne, C.; Pozzi, G.; Serra, M. A.; Clerici, L. A. Nickel, cobalt and chromium-induced cytotoxicity and intracellular accumulation in human hacat keratinocytes. Toxicology, 2001, 159, 23-31.
194. Zhicheng, S. Nickel carbonyl: toxicity and human health. Sci.Total Environ., 1994, 148, 293-298.
195. Shibata, M.; Izumi, K.; Sano, N.; Akagi, A.; Otsuka, H. Induction of soft tissue tumours in F344 rats by subcutaneous, intramuscular, intra-articular, and retroperitoneal injection of nickel sulphide (Ni3S2). J. Pathol., 1989, 157, 263-74.
196. Denkhaus, E.; Salnikow, K. Nickel essentiality, toxicity, and carcinogenicity. Critical Reviews in Oncology/Hematology, 2002, 42, 35-56.
197. Porter, D.W.; Nelson, V.C.; Fivash, M.J.; Kasprzak, K.S. Mechanistic studies of the inhibition of MutT dGTPase by the carcinogenic metal Ni(II). Chem. Res. Toxicol., 1996, 9(8), 1375-81.
198. Karavelas, T.; Mylonas, M.; Malandrinos, G.; Plakatouras, J.C.; Hadjiliadis, N.; Młynarz, P.; Kozłowski, H. Coordination properties of Cu(II) and Ni(II) ions towards the C-terminal peptide fragment - ELAKHA - of histone H2A. J.Inorg.Biochem., 2005, 99, 606-615.
199. Karavelas, T.; Malandrinos, G.; Hadjiliadis, N.; Młynarz, P.; Kozłowski, H.; Barsam, M.; Butler I. Coordination properties of Cu(II) and Ni(II) ions towards the C-terminal peptide fragment - TYTEHA- of histone H4. Dalton Trans., 2008, 1215-1223.
200. Costa, M.; Yan, Y.; Zhao D.; Salnikow, K. Molecular mechanisms of nickel carcinogenesis: gene silencing by nickel delivery to the nucleus and gene activation/inactivation by nickel-induced cell signaling. J. Environ. Monit., 2003, 5, 222-223.
201. Rokita S.E.; Burrows, C.J. In: Metal Ions in Biological Systems; Sigel, A.; Sigel, H., Ed.; Marcel Dekker, New York, 2001; Vol. 38, pp. 289-311.
202. Valko, M.; Rhodes , C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chemico- Biological Interactions, 2006, 160, 1-40.
203. Maier, R.J.; Benoit S.L.; Seshadri, S. Nickel-binding and accessory proteins facilitating Ni-enzyme maturation in Helicobacter pylori. BioMetals, 2007, 20, 655-664.
204. 2+ binding to proteins. Structural and thermodynamic aspects. Coord. Chem. Rev., 2011, doi:10.1016/j.ccr.2011.06.014.
205. Striffler, J.S.; Law, J.S.; Polansky, M.M.; Bhathena, S.J.; Anderson, R.A.; Chromium improves insulin response to glucose in rats. Metabolism, 1995, 44, 1314-1320.
206. Di Bona, K.R.; Love, S.;. Rhodes, N.R.; McAdory, D.; Sinha, S.H.; Kern, N.; Kent, J.; Strickland, J.; Wilson, A.; Beaird, J.; Ramage, J.; Rasco, J.F.; Vincent, J.B.; Chromium is not an essential trace element for mammals: effects of a "low-chromium" diet. Journal of Biological Inorganic Chemistry, 2011, 16, 381-390.
207. Stout, M.D.; Nyska, A.; Collins, B.J.; Witt, K.L.; Kissling, G.E.; Malarkey, D.E.; Hooth, M.J.; Chronic toxicity and carcinogenicity studies of chromium picolinate monohydrate administered in feed to F344/N rats and B6C3F1 mice for 2 years. Food and Chemical Toxicology, 2009, 47, 729-733.
208. Bennett, R.; Adams, B.; French, A.; Neggers, Y.; Vincent, J.B.; High-dose chromium(III) supplementation has no effects on body mass and composition while altering plasma hormone and triglycerides concentrations. Biological Trace Element Research, 2006, 113, 53-66.
209. Król, E.; Krejpcio, Z.; Chromium(III) propionate complex supplementation improves carbohydrate metabolism in insulin-resistance rat model, Food and Chemical Toxicology 48 (2010) 2791-2796
210. Russell III, R.R.; Li, J.; Coven, D.L.; Pypaert, M.; Zechner, C.; Palmeri, M.;. Journal of Clinical Investigation, 2004, 114, 495-503.
211. 3 activates AMP-activated protein kinase and stimulates glucose transport. Biochemical Pharmacology, 2009, 77, 1002.
212. Toneatto, J.; Boero, R.A.; Lorenzatti, G.; Cabanillas, A.M.; Argüello, G.A.; New insights in the DNA-[Cr(phen)2(dppz)]3+ binding and photocleavage properties by the complex with an intercalating ligand. Journal of Inorganic Biochemistry, 2010, 104, 697-703.
213. Toneatto, J.; Argüello, G.A.; New advances in the study on the interaction of [Cr(phen)2(dppz)]3+ complex with biological models; association to transporting proteins. Journal of Inorganic Biochemistry, 2011, 105, 645-651.
214. Sun, Y.; Ramirez, J.; Woski, S.A.; Vincent, J. B.; The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr. Journal of Biological Inorganic Chemistry, 2000, 5, 129-136.
215. Li, Y.; Liu, B.; Yang, B.; Spectroscopic analysis of the interaction between chromium (III) and apoovotransferrin. Journal of Luminescence, 2010, 130, 2339-2345.
216. Nickens, K.P.; Patierno, S.R.; Ceryak, S.; Chromium genotoxicity: A doubleedged sword. Chemico-Biological Interactions, 2010, 188, 276-288.
217. Salnikow, K.; Zhitkovich, A.; Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium, Chemical Research in Toxicology 21 (2008) 28-44
218. Branco, R.; Chung, A.P.; Johnston, T.; Gurel, V.; Morais, P.V.; Zhitkovich, A.; The chromate-inducible chrBACF operon from the transposable element TnOtChr confers resistance to chromium(VI) and superoxide. Journal of Bacteriology, 2008, 190, 6996-7003.
219. Morais, P.V.; Branco, R.; Francisco, R.; Chromium resistance strategies and toxicity: what makes Ochrobactrum tritici 5bvl1 a strain highly resistant. Biometals, 2011, 24, 401-410.
220. Wise Sr., J.P.; Wise, S.S.; Holmes, A.L.; LaCerte, C.; Shaffiey, F.; Aboueissa, A.; The cytotoxicity and genotoxicity of hexavalent chromium in Steller sea lion lung fibroblasts compared to human lung fibroblasts. Comparative Biochemistry and Physiology, Part C, 2010, 152, 91-98.
221. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 58, Beryllium, Cadmium, Mercury, and Exposures in the Glass Manufacturing Industry, 1993.
222. Son, Y-O.; Wang, X.; Hitron, J.A.; Zhang, Z.; Cheng, S.; Budhraja, A.; Ding, S.; Lee J-C.; Shi, X. Cadmium induces autophagy through ROS-dependent activation of the LKB1-AMPK signaling in skin epidermal cells, Toxicology and Applied Pharmacology, 2011, doi:10.1016/j.taap.2011.06.024.
223. Thevenod, F. Catch me if you can! Novel aspects of cadmium transport in mammalian cells. Biometals, 2010, 23, 857-875.
224. Lutzen, A.; Liberti, S.E.; Rasmussen, L.J. Cadmium inhibits human DNA mismatch repair in vivo. Biochem. Biophys. Res. Commun., 2004, 321, 21-25.
225. Templeton, D.M.; Ying, L. Multiple role of cadmium in cell death and survival. Chemico-Biological Interactions, 2010, 188, 267-275.
226. Vesey, D.A. Transport pathways of cadmium in the intestine and kidney proximal tubule: Focus on the interraction with essential metals. Toxicology Letters, 2010, 198, 13-19.
227. Martelli, A.; Rousselet, E.; Dycke, C.; Bouron, A.; Moulis, J.-M. Cadmium toxicity in animal cells by interference with essential metals. Biochimie, 2006, 88, 1807-1814.
228. Stillman, M.J.; Cai, W.; Zelazowski, A.J. Cadmium Binding to Metallothioneins, 1987, 262, pp. 4538-4548.
229. Goyer, R.A.; Cherian, M.G.Handbook of Experimental Pharmacology: Toxicology of Metals, Biochemical Effects, vol. 115, Springer-Verlag, New York, 1994, Chapter: Goering, P.L.; Waalkes, M.P.; Klaassen, C.D. Toxicology of Cadmium, 189-214.
230. Wolfsoon, J.; Heikkila, J.J. Examination of cadmium-induced heat shock protein gene expression in Xenopus laevis A6 kidney epithelial cells. Comparative Biochemistry and Physiology, Part A, 2009, 152, 91-99.
231. Mah, V.; Jalilehvand, F. Cadmium(II) complex formation with glutathione. Journal of Biology Inorganic Chemistry, 2010, 15, 441-458.
232. He, L.; Girijashanker, K.; Daton, T.P.; Reed, J.; Li, H.; Soleimani, M.; Nebert, W.D. ZIP8, member of the solute-carrier-39 (SLC39) metaltransporter family: characterization of transport properties. Molecular Pharmacology, 2006, 70, 171-180.
233. He, L.; Wang, B.; Hay, E.B.; Nebert, W.D. Discovery of ZIP transporters that participate in cadmium damage to testis and kidney. Toxicology and Applied Pharmacology, 2009, 238, 250-257.
234. Fujishiro, H.; Doi, M.; Enomoto, S.; Himeno, S. High sensitivity of RBL- 2H3 cells to cadmium and manganese: an implication of the role of ZIP8. Metallomics, 2011, DOI: 10.1039/c1mt00020a.
235. Suzuki, T.; Momoi, K.; Hosoyamada, M.; Kimura, M.; Shibasaki, T. Normal cadmium uptake in microcytic anemia mk/mk mice suggests that DMT1 is not the only cadmium transporter in vivo. Toxicol. Appl. Pharmacol., 2008, 227, 462-467.
236. Shokooh, S.A.; Fatemi, S. Cadmium transport in blood serum. Toxicology and Industrial Health, 2010, 26, 195-201.
237. Kozyraki, R.; Fyfe, J.; Verroust, P.J.; Jacobsen, C.; Dautry-Varsat, A.; Gburek, J.; Willnow, T.E.; Christensen, E.I.; Moestrup, S.K. Megalindependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 12491-12496.
238. Zalpus, R.K.; Koropatnick, J. Molecular biology and toxycology of metals. Taylor & Francis, London, 2000. Chapter: Shafer T.J. The role of calcium channels in the transport of metals into excitable and nonexcitable cells. 179-207.
239. 2+ channels. Cell Calcium, 2006, 40, 97-114.
240. Lacinova, L.; Klugbauer, N.; Hofmann, F. Regulation of the calcium channel alpha(1G) subunit by divalent cations and organic blockers. Neiropharmacology, 2000, 39, 1254-1266.
241. Smith, A.H.; Steinmaus, C.M. Arsenic in drinking water. British Medical Journal, 2011, doi: 10.1136/bmj.d2248.
242. Yoon, H.S.; Park, T.S.; Jeong, K.H. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure. Pediatric blood & cancer, 2011, doi: 10.1002/pbc.23230.
243. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Human, vol. 23, IARCPress, Lyon, 1980. Some Metals and Metallic Compounds, 39-143.
244. IARC Monographs on the Evaluation of the Carcinogenic Risks of Chemicals to Humans, supplementary 7, IARCPress, Lyon, 1987. An Updating of IARC Monographs Volumes 1-42. 100-106.
245. Raposo, J.C.; Sanz, J.; Zuloaga, O.; Olazabal, M.A.; Madariaga, J.M. The thermodynamic model of inorganic arsenic species in solutions. Potentiometric study of the hydrolytic equilibrium of arsenic acid. Talanta, 2002, 57, 849-857.
246. Rey, N.A.; Howarth, O.W.; Pereira-Maia, E.C. Equilibrium characterization of the As(III)-cysteine and the As(III)-glutathione systems in aqueous solution. Journal of Inorganic Biochemistry, 2004, 98, 1151-1159.
247. Tseng, C.H. A review on environmental factors regulating arsenic methylation in humans. Toxicology and Applied Pharmacology, 2009, 235, 338-350.
248. Naranmandura, H.; Ogra, Y.; Iweta, K.; Lee, J.; Suzuki, K.T.; Weinfeld, M.; Le, X.C. Evidence for toxicity differences between inorganic arsenite and thioarsenicals in human bladder cancer cells. Toxicology and Applied Pharmacology, 2009, 238, 133-140.
249. Narmandura, H.; Suzuki, K.T. Formation of dimethylthioarsenicals in red blood cells. Toxicology and Applied Pharmacology, 2008, 227, 390-399.
250. Rosen, B.P. Biochemistry of arsenic detoxification. FEBS Latters, 2002, 529, 86-92.
251. Tenenhouse, H.S. Phosphate transport: Molecular basis regulation and pathophysiology. Journal of Steroid Biochemistry & Molecular Biology, 2007, 103, 572-577.
252. Sagawa, H.; Aranami, F.; Kaneko, J.; Tomoe, Y.; Miyamoto, K. The roles of Na/Pi-II transporters in phosphate metabolism. Bone, 2009, 45, S2-S7.
253. Villa-Bellost, R.; Sorribas, V. Arsenate transport by sodium/phosphate cotransporter type IIb. Toxicology and Applied Pharmacology, 2010, 247, 36-40.
254. Messens, J.; Silver, S. Arsenate Reduction: Thiol Cascade Chemistry with Convergent Evolution. Journal of Molecular Biology, 2006, 362, 1-17.
255. Thomas, D.J. Molecular processes in cellural arsenic metabolism. Toxicology and Applied Pharmacology, 2007, 222, 365-373.
256. Borgnia, M.; Nielsen, S.; Engel, A.; Agre, P. Cellular and molecular biology of the aquaporin water channels. Annu. Rev. Biochem., 1999, 68, 425-458.
257. Hara-Chikuma, M.; Verkman, A.S. Physiological roles of glyceroltransporting aquaporins: the aquaglyceroporins. Cellular and Mollecular Life Sciences, 2006, 63, 1386-1392.
258. Sun, H. Biological Chemistry of Arsenic, Antimony and Bismuth. John Willey & Sons, 2011, Ltd. Chapter: Fu, H.L.; Jiang, X.; Rosen, B.P. Metalloid Transport System. 181-207.
259. Miao, Z.F.; Chang, E.E.; Tsai, F.Y.; Yeh, S.C.; Wu, C.F.; Wu, K.Y.; Wang, C.J.; Tsou, T.C. Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells. Toxicology in vitro, 2009, 23, 209-216.
260. Liu, Z.; Sanchez, M.A.; Jiang, X.; Boles, E.; Lanfear, S.M.; Rosen, B.P. Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid. Biochemical and Biophysical Research Communications, 2006, 351, 424-430.
261. Liu, Z.; Styblo, M.; Rosen, B.P. Methylarsonous Acid Transport by Aquaglyceroporins. Environmental Health Perspectives, 2006, 114, 527-531.
262. Kala, S.V.; Neely, M.W.; Kala, G.; Prater, C. I.; Atwood, D. W.; Rice, J. S.; Lieberman, M. W. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. The Journal of Biological Chemistry, 2000, 275, 33404-33408.
263. Savory, J.; Exley, C.; Forbes, W,F.; Huang, Y.; Joshi, J.G.; Kruck, T.; McLachlan, D.R.C.; Wakayama, I. Research issues in aluminium toxicity, Taylor and Francis In: Yokel RA, Golub MS, Washington, 1997, 185.
264. McLachlan, D. R.; Fraser, P. E.; Jaikaran, E.; Lukiw, W. J. AD and other Al associated health conditions, in L. W. Chang (Ed): Toxicology of Metals, Lewis Publishers CRC, Bocca Raton, 1996, 387-404.
265. DeVoto, E.; Yokel, R.A.; The biological speciation and toxicokinetics of aluminium. Environmental Health perspectives, 1994, 102 (11), 940-951.
266. Milacic, R.; Speciation of Al in Clinical Aspects, in R. Cornelis, J. Caruso, H. Crews, K. Heumann (Eds): Handbook of Elemental Speciation II: Species in the Environment, Food, Medicine and Occupational Health, Wiley & Sons Ltd, Chichester, 2005, 27-39.
267. Arenas, M.D.;, Malek, T.;, Gil M.T.; Moledous, A.; Nunez, C.; Alvarez-Ude, F. Use of the aluminum phosphate-binders in hemodialysis in the ultrapure water era, Nefrologia 2008, 2, 168.
268. Tonelli, M.; Wiebe, N.; Hemmelgarn, B.; Klarenbach, S.; Field, C.; Manns, B, Thadani, R.; Gill, J. Trace elements in hemodialysis patients: a systematic review and meta-analysis, BMC Med, 2009, 7-25.
269. Alfrey, A.C.; LeGendre, G.R.; Kaehny, W.D.; The dialysis encephalopathy syndrome: possible aluminum intoxication, New England Journal of Medicine, 1976, 294, 184-188.
270. Michalke, B.; Halbach, S.; Nischwitz, V.; JEM Spotlight: Metal speciation related to neurotoxicity in humans, J. Environ. Monit., 2009, 11, 939-954.
271. Kiss, T.; Kilyen, M.; Lakatos, A.; Evanics, F.; Kortvelyesi, T.; Dombi, G.Y.; Majer, Z.S.; Hollosi, M, Interactions of Al(III) with a neurofilement heptapeptide fragment: AcLysSerProValValGluGly, Coord. Chem Rev., 2002, 228, 237-246.
272. Gupta, V.B., S. Anitha, M.L. Hedge, L. Zecca, R.M. Garruto, R. Ravid, S.K. Shankar, R. Stein,. P. Shanmugavelu and K.S. Jagannatha Rao - Aluminium in Alzheimer's disease: are we still at a crossroad? Cell. Mol. Life Sci., 2005, 62, 143-158.
273. Öhman and Martin, Citrate as the main small molecule binding Al3+ in serum, Clinical Chemistry, 1994, 40, 598-601.
274. Yokel, R.A.; Allen, D.D.; Ackley, D.C., The distribution of aluminum into and out of the brain, J. Inorg. Biochem., 1999, 76, 127-132.
275. McLachlan, D. R.; Fraser, P. E.; Jaikaran, E.; Lukiw, W. J.; AD and other Al associated health conditions, in L. W. Chang (Ed): Toxicology of Metals, Lewis Publishers CRC, Bocca Raton, 1996, 387-404.
276. Suwalsky, M.; Norris, B.; Kiss T.; Zatta, P., Effects of Al(III) speciation on cell membranes and molecular models, Coord.Chem. Rev., 2002, 228, 285-295.
277. Exley, Ch., Aluminium and iron, but neither copper nor zinc, are key to the precipitation of [beta]-sheets of A[beta]42 in senile plaque cores in Alzheimer's disease, Journal of Alzheimers Disease, 2006, 10 (2-3), 173-177.
278. Sanz-Medel, A.; Fairman, B.; Wrobel K., Aluminium and Silicon speciation in biological materials of clinical relevance, in S. Caroli, Ed, Element Speciation in Bioorganic Chemistry, 1996, John Wiley & Sons, New York, Chichester, Toronto, 223-254.
279. Zatta, P.; Ibn-Lkhayat-Idrissi, M.; Zambenedetti, P.; Kilyen M.; Kiss, T., Activation of acetylcholinesterase by aluminium(III): The relevance of the metal species, Brain Res. Bulletin, 2002, 41-45.
280. Hollender, D.; Karoly-Lakatos, A.; Forgo, P.; Kortvelyesi, T.; Dombi, G.; Majer, Z.; Hollosi, M.; Kiss, T.; Odani, A., Al(III)-binding ability of an octapeptide and its phosphorylated derivative, J. Inorg. Biochemistry, 2006, 100/3, 351-361.
281. Navak, P.; Chatterjee, A.K., Effects of aluminium exposure on brain glutamate and GABA systems: an experimental study in rats, Food & Chemical Toxicology, Food and Chemical Toxicology, 2001, 39, 12, 1285-1289.
282. Walton, J.R., Bioavailable Aluminium: Its Effects on Human Health, Encyclopedia of Environmental Health, 2011, 331-342.
283. Berthon, G., Chemical speciation studies in relation to aluminium metabolism and toxicity, Coord. Chemistry Reviews, 1996, 149, 241-284.
284. Yokel, R.A.; Allen, D.D.; Ackley, D.C., The distribution of aluminum into and out of the brain, J. Inorg. Biochem., 1999, 76, 127-132.
285. De Voto, E.; Yokel, R.A, The biological speciation and toxicokinetics of aluminium. Environmental Health perspectives, 102/11, 940-951.
286. Michalke, B.; Halbach, S.; Nischwitz, V., JEM Spotlight: Metal speciation related to neurotoxicity in humans, J. Environ. Monit., 2009, 11, 939-954.
287. Crisponi, G.; Nurchi, V.M.; Faa, G.; Remelli, M., Human diseases related to aluminium overload, Monatsh Chem, 2011, 142, 331-340.